Bancej C, Decker K, Chiarelli A, Harrison M, Turner D, Brisson J
Screening and Early Detection, Chronic Disease Prevention Division, Centre for Chronic Disease Prevention and Control, Health Canada.
J Med Screen. 2003;10(1):16-21. doi: 10.1258/096914103321610761.
As the benefit of clinical breast examination (CBE) over that of screening mammography alone in reducing breast cancer mortality is uncertain, it is informative to monitor its contribution to interim measures of effectiveness of a screening programme. Here, the contribution of CBE to screening mammography in the early detection of breast cancer was evaluated.
Four Canadian organised breast cancer screening programmes.
Women aged 50-69 receiving dual screening (CBE and mammography) (n = 300,303) between 1996 and 1998 were followed up between screen and diagnosis. Outcomes assessed by mode of detection (CBE alone, mammography alone, or both CBE and mammography) included referral rate, positive predictive value, pathological features of tumours (size, nodal status, morphology), and cancer detection rates overall and for small cancers (< or = 10 mm or node-negative). Heterogeneity in findings across programmes was also assessed.
On first versus subsequent screen, CBE alone resulted in 28.5-36.7% of referrals, and 4.6-5.9% of cancers compared with 52.6-60.1% of referrals and 60.0-64.3% of cancers for mammography alone. Among cancers detected by CBE, 83.6-88.6% were also detected by mammography, whereas for mammographically detected cancers only 31.7-37.2% were also detected by CBE. On average, CBE increased the rate of detection of small invasive cancers by 2-6% over rates if mammography was the sole detection method. Without CBE, programmes would be missing three cancers for every 10,000 screens and 3-10 small invasive cancers in every 100,000 screens.
Inclusion of CBE in an organised programme contributes minimally to early detection.
由于临床乳腺检查(CBE)相较于单纯的乳腺筛查钼靶检查在降低乳腺癌死亡率方面的益处尚不明确,监测其对筛查项目有效性中期指标的贡献具有参考价值。在此,评估了CBE在乳腺癌早期检测中对乳腺筛查钼靶检查的贡献。
四个加拿大有组织的乳腺癌筛查项目。
对1996年至1998年间接受双重筛查(CBE和钼靶检查)的50 - 69岁女性(n = 300,303)进行筛查至诊断期间的随访。通过检测方式(单独CBE、单独钼靶检查或CBE和钼靶检查两者)评估的结果包括转诊率、阳性预测值、肿瘤的病理特征(大小、淋巴结状态、形态)以及总体和小癌症(≤10毫米或无淋巴结转移)的癌症检测率。还评估了各项目结果的异质性。
在首次与后续筛查中,单独CBE导致28.5% - 36.7%的转诊,以及4.6% - 5.9%的癌症,而单独钼靶检查导致52.6% - 60.1%的转诊和60.0% - 64.3%的癌症。在CBE检测出的癌症中,83.6% - 88.6%也被钼靶检查检测到,而在钼靶检查检测出的癌症中,只有31.7% - 37.2%也被CBE检测到。平均而言,与仅以钼靶检查作为唯一检测方法相比,CBE将小浸润性癌的检测率提高了2% - 6%。如果没有CBE,每10000次筛查各项目会漏诊3例癌症,每100000次筛查会漏诊3 - 10例小浸润性癌。
在有组织的项目中纳入CBE对早期检测的贡献极小。